Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes

Aicardi-Goutières Syndrome (AGS) Clinical Trial

Official title:
Compassionate Use Treatment Protocol I4V-MC-JAGA: Treatment of Conditions Expected to Benefit From JAK 1/2 Inhibition: CANDLE, CANDLE-Related Conditions, SAVI and Severe Juvenile Dermatomyositis

Status No longer available

Clinical Trial Summary

The Requesting Physician/Investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Aicardi-Goutières Syndrome (AGS)
Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE)
Dermatomyositis
Fever
Hyperthermia
Juvenile Dermatomyositis (JDM)
Lipodystrophy
Skin Diseases
Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset During Infancy (SAVI)
Syndrome

Clinical Trial Details

NCT number	NCT01724580
Study type	Expanded Access
Source	Eli Lilly and Company
Contact
Status	No longer available
Phase

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT02363452` - Reverse Transcriptase Inhibitors in AGS	Phase 2
	Recruiting	`NCT05613868` - TPN-101 in Aicardi-Goutières Syndrome (AGS)	Phase 2